Bacterial strain for promoting GLP-1 secretion and application thereof

Abstract

The invention discloses a bacterial strain for promoting GLP-1 secretion and application of the bacterial strain. The bacterial strain is Lactobacillus plantarum HP59, is preserved in Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC NO.64841. The invention also discloses a preparation method of the bacterial strain for promoting GLP-1 secretion and application of the bacterial strain for promoting GLP-1 secretion. The preservation time is July 8, 2024; the strain for promoting GLP-1 secretion can regulate the secretion level of GLP-1 in the intestinal tract and can promote expression of GLP-1 in the intestinal tract, so that blood sugar is reduced, obesity symptoms are improved, and the purpose of reducing the weight and blood sugar of obese people is achieved.

Description

Technical Field

[0001] The present invention relates to the field of microbial technology, and in particular to a strain for promoting GLP-1 secretion and application thereof. Background Art

[0002] Glucagon-like peptide-1 (GLP-1) is a hormone mainly produced by intestinal L cells and belongs to the incretin group.

[0003] Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a new type of hypoglycemic drug in recent years. It activates GLP-1 receptors, enhances insulin secretion in a glucose concentration-dependent manner, inhibits glucagon secretion, and can delay gastric emptying. It reduces food intake through central appetite suppression, thereby achieving the effects of lowering blood sugar and losing weight.

[0004] As a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) / glucagon receptor (GCGR), Mashidu peptide is a mammalian gastrin modulator (OXM) analog. In addition to promoting insulin secretion, lowering blood sugar and regulating body weight by stimulating GLP-1R, it can also increase energy consumption by stimulating GCGR to enhance weight loss efficacy and improve liver fat metabolism. Mashidu peptide has demonstrated excellent weight loss and blood sugar lowering effects in many clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, blood uric acid, liver enzymes and liver fat content, while improving insulin sensitivity and bringing multiple metabolic benefits.

[0005] Therefore, it is very necessary to provide a product that can promote the secretion of GLP-1 for lowering blood sugar, losing weight, etc. Summary of the invention

[0006] The purpose of the present invention is to provide a strain that promotes GLP-1 secretion and its application. The strain that promotes GLP-1 secretion of the present invention can regulate the secretion level of intestinal GLP-1 and has a certain therapeutic effect on lowering blood sugar, improving obesity and the like.

[0007] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0008] The first aspect of the present invention provides a strain that promotes GLP-1 secretion, wherein the strain is Lactobacillus plantarum HP59, which is deposited in Guangdong Provincial Microbiological Culture Collection Center with a deposit number of GDMCC NO.64841; the deposit time is July 8, 2024.

[0009] The second aspect of the present invention provides a microbial agent containing the strain that promotes GLP-1 secretion.

[0010] Preferably, the microbial agent is a solid preparation or a liquid preparation.

[0011] Preferably, the microbial agent comprises inoculating the strain that promotes GLP-1 secretion into a culture medium for culturing.

[0012] The third aspect of the present invention provides a use of the strain promoting GLP-1 secretion or the microbial agent in promoting GLP-1 secretion.

[0013] The fourth aspect of the present invention provides a product for promoting GLP-1 secretion, wherein the product comprises the strain for promoting GLP-1 secretion or the microbial agent.

[0014] Preferably, the product is a food or a medicine.

[0015] Compared with the prior art, the beneficial effects of the present invention include at least:

[0016] The strain promoting GLP-1 secretion of the present invention can regulate the secretion level of intestinal GLP-1 and promote the expression of GLP-1 in the intestine, thereby being beneficial to lowering blood sugar and improving obesity symptoms, thereby achieving the purpose of reducing the weight and blood sugar of obese people. DETAILED DESCRIPTION

[0017] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the embodiments. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0018] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should have the common meanings understood by those skilled in the art to which the present invention belongs.

[0019] The embodiment of the present invention provides a first aspect of the present invention provides a strain that promotes GLP-1 secretion, wherein the strain is Lactobacillus plantarum HP59, which is deposited in Guangdong Provincial Microbiological Culture Collection Center with a deposit number of GDMCC NO.64841; the deposit time is July 8, 2024.

[0020] The strain promoting GLP-1 secretion of the present invention can regulate the secretion level of intestinal GLP-1 and promote the expression of GLP-1 in the intestine, thereby being beneficial to lowering blood sugar and improving obesity symptoms, thereby achieving the purpose of reducing the weight and blood sugar of obese people.

[0021] Another embodiment of the present invention provides a microbial agent containing the strain that promotes GLP-1 secretion.

[0022] In one embodiment, the microbial agent is a solid preparation or a liquid preparation.

[0023] Furthermore, the solid preparation may be a lyophilized powder.

[0024] In one embodiment, the microbial agent comprises inoculating the strain that promotes GLP-1 secretion into a culture medium for culturing.

[0025] Another embodiment of the present invention provides a use of the strain promoting GLP-1 secretion or the microbial agent in promoting GLP-1 secretion.

[0026] Still another embodiment of the present invention provides a product for promoting GLP-1 secretion, wherein the product comprises the strain for promoting GLP-1 secretion or the microbial agent.

[0027] In one embodiment, the product is a food or a medicine.

[0028] The technical solution of the present invention is further described in detail below through specific embodiments.

[0029] Example 1

[0030] This example is the screening of Lactobacillus plantarum HP59:

[0031] Several samples of traditional fermented cheese from Xinjiang were collected using a disposable sterile sampler. After gradient dilution, they were applied to LBS culture medium supplemented with 1% nystatin and enriched in an anaerobic incubator for 48 hours. After cultivation, colonies were picked with an inoculation loop and streaked for purification based on their color, size, edge shape, etc. After identification, a strain of Lactobacillus plantarum HP59 was obtained.

[0032] The morphological identification characteristics of Lactiplantibacillus plantarum HP59 are as follows: curved rod-shaped under a microscope, the colonies are dark yellow and convex.

[0033] Example 2

[0034] This example is the preparation of Lactobacillus plantarum HP59 liquid inoculum:

[0035] Lactobacillus plantarum HP59 was inoculated into MRS liquid culture medium and cultured at 37° C. for 48 hours to obtain a microbial preparation.

[0036] Example 3

[0037] This example is a study on the GLP-1 secretion performance of Lactobacillus plantarum HP59:

[0038] STC-1 cells were inoculated into a 48-well plate. When the cells grew to 80% confluence, the experimental group: STC-1 cells were inoculated with 10% volume of the microbial preparation of Example 2 (1×10 9 cfu / ml) and STC-1 cells were cultured in a 37°C incubator for 24 h; blank control: STC-1 cells were inoculated with 10% MRS liquid culture medium and cultured in a 37°C incubator for 24 h;

[0039] Then, the culture medium was collected and centrifuged at 1200 r / min for 10 min at 4 °C, and the supernatant was collected. This was repeated three times;

[0040] Subsequently, the GLP-1 detection ELISA kit was used for detection, and the detection method was carried out according to the kit instructions.

[0041] Experimental results:

[0042] Compared with the blank control, the average GLP-1 content in the supernatant of STC-1 cells in the experimental group was 43.1 pM, however, the average GLP-1 content in the supernatant of STC-1 cells in the blank control group was 1.3 pM; it can be seen that Lactobacillus plantarum HP59 of the present application can significantly promote the secretion of GLP-1.

[0043] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. A strain that promotes GLP-1 secretion, characterized in that: The strain is Lactobacillus plantarum HP59, which is preserved in Guangdong Provincial Microbiological Culture Collection Center with the preservation number GDMCC NO.64841; the preservation time is July 8, 2024.

2. A microbial agent containing the strain that promotes GLP-1 secretion according to claim 1.

3. The microbial agent according to claim 2, characterized in that: The microbial agent is a solid preparation or a liquid preparation.

4. The microbial agent according to claim 2, characterized in that: The microbial agent comprises inoculating the strain promoting GLP-1 secretion into a culture medium for culturing.

5. Use of the strain for promoting GLP-1 secretion according to claim 1 or the microbial agent according to any one of claims 2 to 4 in promoting GLP-1 secretion.

6. A product for promoting GLP-1 secretion, characterized in that: The product comprises the strain promoting GLP-1 secretion according to claim 1 or the microbial agent according to any one of claims 2 to 4.

7. The product according to claim 6, characterized in that The product is a food or a medicine.